Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer

NCT07552181 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer
TNBC
Early Stage Triple-Negative Breast Carcinoma

Interventions

DRUG: Live biotherapeutic product: MO-03 1 capsule PO BID

Sponsor

Yuan Yuan

Collaborators

[object Object]
[object Object]